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Localization of lanthanum in bone of chronic renal failure rats
after oral dosing with lanthanum carbonate.
Background. Lanthanum carbonate has been shown to be a
safe, effective phosphate-binding agent. We have shown that
an impaired mineralization in chronic renal failure rats treated
with high doses of lanthanum carbonate develops secondary to
phosphate depletion and is therefore pharmacologically medi-
ated rather than a direct effect of lanthanum on bone. Although
bulk bone lanthanum concentrations are low, it is important to
consider the localization within a given tissue.
Methods. Using the scanning x-ray micro-fluorescence set-
up at beamline ID21 of the European Synchrotron Radiation
Facility, calcium and lanthanum distributions in bone samples
were mapped.
Results. In chronic renal failure rats loaded orally with lan-
thanum carbonate (12 weeks) (2000 mg/kg/day), bulk bone lan-
thanum concentrations reached values up to 5 lg/g wet weight.
Lanthanum could be demonstrated at the edge of the miner-
alized bone, at both actively mineralizing and quiescent sites,
independent of the type of bone turnover. In the presence of
hyperparathyroid bone disease, lanthanum was also distributed
throughout the mineralized trabecular bone. No correlation
with the presence of osteoid, or the underlying bone pathology
could be demonstrated. After a 2- or 4-week washout period
before sacrifice, lanthanum localization did not change signifi-
cantly.
Conclusion. The comparable localization of lanthanum in dif-
ferent types of bone turnover, and the unchanged localization
after washout and consequent disappearance of the mineraliza-
tion defect, indicates no relationship between the localization of
lanthanum in bone and the presence of a mineralization defect.
Adequate control of phosphate status remains an im-
portant issue in the management of renal failure patients.
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In addition to dietary restrictions, the use of phosphate
binding agents is often necessary. The therapeutic use of
the most common phosphate binders (aluminum hydrox-
ide, calcium salts) can result in serious side-effects, such as
bone mineralization defects, toxicity at the level of other
organs, and induction of extraosseous calcifications [1].
In the search for new, effective, and safe alternatives, lan-
thanum carbonate [La2(CO3)3] (Fosrenol®) has recently
been proposed.
Lanthanum belongs to the group of the rare earth ele-
ments, and is strongly electro-positive. Hence, its most
common biologic ligands are carboxyl and phosphate
groups (PO43−) with which it can form very tight, insol-
uble complexes. The systemic absorption of lanthanum
is very low, estimated in humans to be 0.00089%, and
does not differ significantly between dialysis patients and
subjects with normal renal function [abstract; Pennick M
et al, XLI ERA-EDTA Congress Abstract Book 105,
2004].
We have previously shown that a mineralization de-
fect can develop in chronic renal failure rats after 12
weeks of treatment with lanthanum carbonate at doses
≥ 1000 mg/kg/day [2]. This mineralization defect was
found to occur secondary to a severe phosphate depletion
induced by the compound’s powerful phosphate bind-
ing rather than being the result of a direct effect of lan-
thanum on bone. This hypothesis is further supported
by our findings that a similar mineralization defect can
also be induced by sevelamer, a nonmetal-containing,
nonabsorbed polymeric phosphate binding agent [ab-
stract; Behets GJ et al, J Am Soc Nephrol 12:740A, 2001],
and the findings by Damment et al [abstract; Damment
SJP et al, Nephrol Dial Transplant 17:67, 2002], show-
ing that systemic phosphate repletion during lanthanum
carbonate treatment can prevent this mineralization de-
fect. Furthermore, in contrast to what has previously been
observed with the aluminum-induced osteomalacia [3,
4], the mineralization defect seen with lanthanum car-
bonate does not affect osteoblasts [2]. Recently, we have
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also shown that the mineralization defect noted after lan-
thanum carbonate treatment reverses to “normal” (for
chronic renal failure animals) within 2 to 4 weeks after
withdrawal of lanthanum carbonate, without any change
in the bulk bone lanthanum concentrations [abstract; Be-
hets GJ et al, J Am Soc Nephrol 14:205A, 2003]. Using
paired bone biopsies, taken in dialysis patients before
and after a 1-year treatment with lanthanum carbonate
or calcium carbonate, D’Haese et al [5] have shown no
evolution toward low bone turnover in the lanthanum
carbonate–treated group, and no aluminum-like effects
on bone.
Although not strictly belonging to the group of the lan-
thanides, lanthanum has a close chemical resemblance
to these metals, and is often implicitly included in this
group. The distribution of trivalent lanthanides and ac-
tinides in humans and animals has been extensively stud-
ied using radioactive isotopes (reviewed in [6]). In blood,
these ions are found mainly bound to plasma proteins.
Accumulation above average occurs mainly in liver,
skeleton, and kidney. In bone, all trivalent actinide and
lanthanide elements behave similarly, and are deposited
on bone surfaces. Interestingly, some of these (such as
americium or ceurium) are not only found on sites of bone
formation, but also concentrated along sites of bone re-
sorption. The mechanism of this localization is not clear
[6]. Once deposited, the metals can become incorporated
into the bone matrix during subsequent bone formation.
During bone resorption, these elements can re-enter the
systemic blood supply or be redeposited onto new bone
surfaces, possibly after transfer through osteoclasts and
macrophages [6].
Aside from bone, there is also some retention of lan-
thanum in other tissues, mainly the liver. In brain tissue
and cerebrospinal fluid, lanthanum concentrations range
from below the detection limit to <0.1 lg/g in animals
(rats, dogs, and mice) dosed for up to 80 weeks with
2000 mg/kg/day of lanthanum carbonate [abstract; Dam-
ments SJP et al, J Am Soc Nephrol 14:204A, 2003]. Bone
lanthanum levels of chronic renal failure rats treated
with high doses (≥ 1000 mg/kg/day) rarely exceed 5 lg/g
[2] [abstract; Damments SJP et al, J Am Soc Nephrol
14:204A, 2003]. In patients treated for up to 4 years with
lanthanum carbonate, bone lanthanum concentrations
are consistently below 10 lg/g (Shire Pharmaceutical De-
velopment, unpublished results). Compared to bone alu-
minum levels noticed in the past in aluminum-treated pa-
tients (100 to 200 lg/g) [7], the observed lanthanum levels
are one to two orders of magnitude lower. It is of note,
however, that as shown previously for aluminum, abso-
lute concentrations do not accurately reflect the possible
toxic effects in a particular tissue. As an example, while
brain aluminum levels are 10- to 20-fold lower than those
noticed in the liver, severe neurotoxic effects may occur
in the absence of any hepatic toxicity [8]. This has been
ascribed to the element’s subcellular localization. Indeed,
in the liver, aluminum is sequestered in the lysosomes of
Kupffer cells, thereby preventing the element from exert-
ing its toxic effect [9, 10], while in the brain, it circulates
in its free state (i.e., nonprotein-bound), which may de-
termine the element’s high toxicity at this site [11]. Bone
toxicity of aluminum also has been found to be highly
dependent on its histologic localization. While bone alu-
minum levels in hyperparathyroid bone may be as high
as those observed in osteomalacia, no toxic effects are
seen in the former case where the element is diffusely
distributed throughout the bone [12]. In osteomalacia,
aluminum is mainly localized at the mineralization front,
where it has been hypothesized to directly interfere with
mineralization, although no clear-cut data evidencing this
have been published so far.
In order to gain a better insight in lanthanum’s be-
havior at the bone level, the localization of the element
and its local concentration at a particular site within the
bone are of particular interest. However, the low con-
centrations present a major technical difficulty in terms
of sensitivity. No histochemical staining procedure is
available, and techniques such as Electron Probe X-Ray
Microanalysis (EPXMA) or Laser Microprobe Mass
Analysis (LAMMA) are not sensitive enough to detect
the lanthanum. In the present study, we used x-ray mi-
crofluorescence at the European Synchrotron Radiation
Facility (Grenoble, France), enabling us to combine the
required spatial resolution (lm range) with the necessary
sensitivity (ppm range) to investigate lanthanum localiza-
tion in bone from chronic renal failure rats.
METHODS
This study was performed as an extension of a study on
the time course and effects of the incorporation/efflux of
lanthanum into/out of bone (Bervoets AR, manuscript in
preparation). Out of the 31 available bone samples, ten
were selected according to the bone lanthanum content
and bone histology. These samples covered the various
types of renal osteodystrophy.
Animals
Male Wistar rats (200 to 250 g at start of experiment
(N = 31) underwent a 5/6 nephrectomy to induce chronic
renal failure. After a 2-week stabilization period, the an-
imals received daily oral gavages with 2000 mg/kg/day
lanthanum carbonate [La2 (CO3)3 · 4H2O] (Shire Phar-
maceutical Development Ltd., Basingstoke, UK), sus-
pended in 2% carboxymethylcellulose (Sigma-Aldrich
N.V., Bornem, Belgium). A constant dose volume of 10
mL/kg was used. All animals were weighed weekly, and
the individual doses were adjusted according to the most
recently recorded body weight. Control animals (N = 6)
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received vehicle only. At the end of the 12-week loading
period, animals were either sacrificed immediately (N =
8) or after a 2- or 4-week washout period (N = 9 and
N = 8, respectively). In order to evaluate dynamic bone
parameters, all animals received tetracyclin (30 mg/kg)
and demeclocyclin (25 mg/kg) by intraperitoneal injec-
tion at 7 and 3 days before sacrifice.
At the end of the treatment periods, animals were sac-
rificed by exsanguination through the abdominal aorta
after sodium pentobarbital (Nembutal®) (Ceva Sante´
Animale, Brussels, Belgium) anesthesia. Both tibias were
removed, dissected free of soft tissue, fixed in Burkhardt’s
fixative for 24 hours at 4◦C and transferred to 70%
ethanol until further processing. The right femur was
immediately wet weighed, and stored dry at −80◦C un-
til analysis for bulk lanthanum content using inductively
coupled plasma-mass spectrometry (ICP-MS).
Preparation of bone samples
The tibias were dehydrated in increasing ethanol con-
centrations and impregnated for 1 week with methyl-
methacrylate monomer. Afterwards, polymerization was
allowed to proceed for 48 hours under N2 atmosphere.
Five micrometer thick Goldner stained sections, and 10
lm thick unstained sections were used to perform his-
tomorphometric analysis. All animals were individually
classified according to the type of renal osteodystrophy
by comparison of the histomorphometric results with his-
toric controls of animals of the same age, gender, and
strain, taking into account biochemical parameters. Out
of the available bone samples, the samples showing the
highest bulk bone lanthanum content and presenting the
different types of renal osteodystrophy were chosen for
further analysis (N = 3 of each treatment group and one
control). A 10 lm thick section was dried unstained be-
tween two glass cover slides at 60◦C, and used for the
x-ray microfluorescence analysis, while an adjacent, se-
rial section was Goldner-stained and used to correlate
the x-ray fluorescence results with light microscopy.
X-ray microfluorescence
In view of the low lanthanum concentrations, a tech-
nique like x-ray microfluorescence, offering a high
sensitivity for trace element detection, is particularly suit-
able. Current third generation synchrotron sources can
provide x-rays with a brilliance that is 10 to 11 orders
of magnitude greater than conventional laboratory x-ray
tubes. This high brilliance coupled with technologic ad-
vances in the manufacturing of x-ray focusing optics now
provide intense x-ray microprobes for spatially resolved
microanalysis.
The X-ray Microscopy Beamline ID21 of the Euro-
pean Synchrotron Radiation Facility (Grenoble, France)
is dedicated to x-ray microfluorescence and microspec-
troscopy [13]. The x-ray primary excitation energy is se-
lected using a double crystal Si (111) monochromator
tuned to 6.3 keV (i.e., above the L edge energy level of
lanthanum). In the scanning x-ray microscope, the beam
is then focused using a Fresnel zone plate (provided by E.
Di Fabrizio, TASC-INFM, Trieste, Italy) to a probe size
of approximately 1 lm with an intensity of 7 × 109 pho-
tons/seconds/Si (111) band width. The sample is mounted
at a 45◦ angle to the incident beam and x-ray fluorescence
is detected using a high-energy resolution germanium
(Ge) energy-dispersive solid-state detector, placed at a
90◦ angle to the incident beam. To avoid saturation of the
detector by the intense calcium K lines signal, a 240 lm
Kapton® filter was mounted just in front of the detector,
introducing a differential attenuation of calcium K lines
(∼90%) and higher energy lanthanum L lines (66%). A
visible light videomicroscope mounted inside the scan-
ning x-ray microscope allows precise positioning of the
region of interest of the sample in the beam.
In order to produce two-dimensional images, the sam-
ple was raster scanned in the microfocused beam, and a
full x-ray fluorescence spectrum recorded for every pixel
(energy range 0 to 10 keV, 4096 channels). Calcium and
lanthanum mappings are constructed by integrating the
appropriate energy windows of their respective fluores-
cence x-rays (calcium 3.53 to 4.12 keV and lanthanum
4.92 to 5.93 keV). Full spectral counts are retained for
each pixel to verify the presence of lanthanum, and elim-
inate possible interference of other elements (titanium,
vanadium, etc.). All images were corrected for variations
in the incoming beam intensity using the signal generated
by a photodiode mounted upstream the sample.
Synthetic hydroxyapatite standards were synthesized
based on the method of Sun et al [14] using co-
precipitation of NaH2PO4 with CaCl2 and LaCl3 at
known molar lanthanum/(lanthanum + calcium) ratios
(1, 0.75, 0.50, 0.25, and 0 mol%) in an alkaline environ-
ment. These standards were used to construct a stan-
dard curve of the lanthanum/calcium fluorescence ratio
vs. the lanthanum/(calcium + lanthanum) concentrations.
The measurements on the reference lanthanum-doped
apatites were performed in the same focused configu-
ration as for the bone samples. The ratio of the lan-
thanum/calcium fluorescence windows, as defined above,
was simply calculated without fluorescence yield or reab-
sorption correction to obtain a direct calibration curve of
the lanthanum concentrations.
RESULTS
Analytic aspects
Detailed biochemical and histomorphometric results
will be published elsewhere (Bervoets AR, manuscript
in preparation). In summary, biochemical parameters in-
dicated that all animals had developed a stable renal in-
sufficiency. Bulk bone lanthanum concentrations were
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Fig. 1. A typical x-ray fluorescence spectrum collected in focused mode
on a bone sample with identification of the major energy lines identi-
fied. The shaded area surrounding the calcium (Ca) Ka and Kb peaks
and the lanthanum (La) Lb 1, Lb 2 and Lc1 peaks indicate the energy
windows used to create the calcium and lanthanum images (excitation
x-ray energy 6.3 keV, integration time 60 seconds).
approximately 2 to 3 lg/g wet weight in lanthanum-
treated animals, and did not decrease during the washout
periods. Control animals showed bone lanthanum con-
tent <0.5 lg/g wet weight. Bone histomorphometry
showed the presence of different types of renal os-
teodystrophy (mineralization defect, hyperparathyroid
bone, mixed lesions) in the animals. Although bulk bone
lanthanum content did not change during the washout
periods, bone histology improved, with fewer animals
showing a mineralization defect.
Figure 1 shows a typical x-ray fluorescence spectrum
with indication of the major fluorescence peaks for cal-
cium and lanthanum. The measured energy levels and rel-
ative intensities for calcium and lanthanum peaks are in
accordance with classic x-ray database values. In view of
the abundance of calcium in the samples, and to avoid any
possible overlap of the calcium Kb with the lanthanum
La peaks, the energy window for subsequent analysis was
chosen to cover the lanthanum Lb and Lc peaks.
Using synthetic hydroxyapatite, doped with known lan-
thanum concentrations, lanthanum and calcium signals
could clearly be detected. The lanthanum/calcium fluo-
rescence ratios varied from 0.0006 to 0.1091, with excel-
lent linearity (y = 0.1098× + 0.001, r = 0.99935) (Fig. 2).
This curve was used to estimate local lanthanum/calcium
ratios and lanthanum concentrations.
Localization of lanthanum in bone
In an animal with normal bone histology (bulk bone
lanthanum concentration 2.68 lg/g wet weight), lan-
thanum could be localized at the outer edge of the
mineralized bone (Fig. 3A) at different sites along the tra-
becular bone perimeter. It was found on quiescent bone
as well as adjacent to an area covered with osteoid (ac-
tive mineralization site), and in a resorption lacuna. No
obvious colocalization with osteoid could be found.
In hyperparathyroid bone (bulk bone lanthanum
2.17 lg/g), the observed localization was similar (Fig. 3B),
that is at the edge of the calcified bone, whether or not
covered with osteoid. Additionally, significant amounts
of lanthanum could also be found inside the trabecular
bone.
In addition, in an animal showing a mineralization de-
fect (bulk bone lanthanum 2.81 lg/g), the localization of
lanthanum was comparable (Fig. 3C). As shown in the
lower panel of Figure 3C, the presence of an enlarged
osteoid seam could not be associated with an increased
lanthanum deposition at the mineralization front.
Interestingly, in all examined bone samples, the highest
lanthanum concentrations appeared slightly in front of
the calcified bone perimeter (Fig. 3, white arrows). In
animals receiving vehicle only, no lanthanum could be
demonstrated (results not shown).
After a 2- or 4-week washout period, the localization
of lanthanum had not changed significantly, as lanthanum
could still be found at the edge of both quiescent and
active sites of mineralization.
At the locations showing the highest lanthanum con-
centrations, local molar lanthanum/(lanthanum + cal-
cium) ratios were estimated using the lanthanum/calcium
fluorescence ratios. These were consistently found to be
below 0.05 mol%, in other words, in no case did lan-
thanum replace more than 1 out of 2000 calcium atoms
within the hydroxyapatite. No significant differences in
the lanthanum/(lanthanum + calcium) ratios were no-
ticed between animals showing different types of renal
osteodystrophy.
DISCUSSION
Because of the low concentrations at which lanthanum
is present in bone, histochemical staining methods or con-
ventional instrumental techniques such as electron probe
x-ray microanalysis or laser microprobe mass analysis are
either not available, or do not attain a high enough sen-
sitivity to localize the element within trabecular bone.
Hence, more sophisticated techniques have to be applied.
X-ray microfluorescence, used at beamline ID21 of
the European Synchrotron Radiation Facility (Greno-
ble, France), attains the analytic performance (i.e., a high
enough spatial resolution and sensitivity) required to lo-
calize lanthanum in bone. Due to the great demand for
beam-time at the European Synchrotron Radiation Facil-
ity and the rather long acquisition times per image (sev-
eral hours), only a limited number of samples (N = 10)
could be analyzed. Hence, a selection of samples show-
ing the main types of renal osteodystrophy and having
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Fig. 2. Standard curve. Synthetic hydroxyapatite doped with known lanthanum concentrations was used to measure the lanthanum/calcium (La/Ca)
fluorescence ratio (linear regression: y = 0.1098× + 0.001; r = 0.99935).
comparable bulk lanthanum contents (2 to 3 lg/g) was
made for further analysis.
Using samples from animals loaded with lanthanum
carbonate for 12 weeks, lanthanum was located at the
outer edge of the calcified bone, independent of the pres-
ence or amount of osteoid or of the type of renal os-
teodystrophy. During short-term washout, no significant
changes in localisation were observed and bulk bone
lanthanum concentrations in the uremic rats remained
unchanged despite a distinct improvement of the bone
histology (Bervoets AR, manuscript in preparation) [ab-
stract; Behets GJ et al, J Am Soc Nephrol 14:205A, 2003].
This further suggests that lanthanum’s effects on bone
mineralization are indirect and unrelated to the element’s
presence in bone.
The exact mechanism by which lanthanum is incorpo-
rated in the mineralized bone is unclear. Our results show
that lanthanum is mainly found adjacent to the calcified
bone at both quiescent and active sites of mineralization,
and also deeper inside the trabecular bone, particularly
in animals showing a high bone turnover. In an extensive
review on the biologic behavior of aluminum in humans,
Priest [15] suggested several mechanisms that could be
responsible for metal (including lanthanum) accumula-
tion in bone. The first mechanism consists of heteroionic
exchange with calcium (either in the bone crystal or the
hydration shell). The presence of lanthanum at quiescent
sites is compatible with such a mechanism, and is likely
a nonspecific precursor to exchange with the mineral
matrix itself [6]. Second, coprecipitation of lanthanum
phosphate and/or incorporation of lanthanum into the
hydroxyapatite crystal may be hypothesised. The in vitro
experiments of Mayer et al [16] indicate that lanthanum
ions are unlikely to incorporate directly into the hydrox-
yapatite crystal, but are more likely to precipitate as
amorphous lanthanum phosphate. With either mecha-
nism, lanthanum may be incorporated into the deeper
layers of the bone during active mineralization, which is
in line with the diffuse distribution of lanthanum, par-
ticularly under conditions of high bone turn-over. This
“trapped” lanthanum can be expected to resist back ex-
change with tissue fluids, and thus be relatively fixed
inside the bone mineral [6]. Finally, there might be
complexation with organic components of the bone ma-
trix, known to play a role in apatite nucleation. Given
the high affinity of lanthanum for phosphate, binding to
organic components of the bone matrix (such as phos-
phoproteins) is likely to occur, and has already been
shown in vitro [6]. This mechanism could explain that
the increase in lanthanum concentration is found ahead
of the increasing calcium concentrations, as reflected by
the concentration profiles. However, in view of the very
low concentrations (vs. calcium) at which lanthanum is
present in bone, an interference with apatite nucleation
is unlikely. Indeed, using synthetic lanthanum-doped hy-
droxyapatite, local lanthanum concentrations were es-
timated to account only for 0.05 mol% of the calcium
content in the highest lanthanum-enriched areas of the
bone. This means that maximally one out of every 2000
calcium atoms might be replaced by lanthanum. Under
conditions of high bone turnover, a more homogenous
distribution of lanthanum was found and the lanthanum
to calcium ratio was one or two orders of magnitude
less. A direct physicochemical interference of lanthanum
with mineralization is therefore unlikely. In contrast, bulk
bone aluminum concentrations in patients exposed to
aluminum can increase up to values ≥50 lg/g. Assum-
ing a bone calcium concentration of 120 mg/g [17] and
a local accumulation of aluminum in only 1% of the to-
tal, mineralized bone volume, more than 1 in 15 calcium
atoms will be replaced by aluminum.
Following previous findings with aluminum, one
should also consider a possible interference of lan-
thanum with osteoblast activity. In contrast to the
aluminum-induced mineralization defect, however, ac-
tive cuboidal osteoblasts are still present in the lanthanum
Behets et al: Localization of lanthanum in bone of chronic renal failure rats 1835
C
B
A
Goldner staining Fluorescence images
Ca La LaCa
Composite
image
Fig. 3. Lanthanum localization in different types of renal osteodystrophy (ROD). The left column shows Goldner-stained sections with the region
used for localization marked. Adjacent, unstained sections were used for x-ray microfluorescence. The right column shows calcium and lanthanum
gray-scale images, and a resulting composite image (calcium, red; lanthanum, green). Overlaid on the composite images are the integrated fluores-
cence intensities for calcium (blue) and lanthanum (green) along the profiles indicated by the arrows. Each panel shows representative results of an
animal with a distinct type of renal osteodystrophy. (A) Animal with normal bone histology (bulk bone lanthanum 2.68 lg/g) showing lanthanum
localized at the outer edge of the mineralized bone in a resorption lacuna (top) and underlying an area of osteoid (bottom). (B) Animal showing
hyperparathyroid bone disease (bulk bone lanthanum 2.17 lg/g). Similar localization at the edge of the calcified bone, but not colocalized with the
osteoid. Also note the presence of lanthanum deeper inside the calcified bone. (C) Animal with a mineralization defect (bulk bone lanthanum 2.81
lg/g). Note in the lower part of the figure the presence of a large osteoid seam, without lanthanum at the mineralization front. Also note in the line
graphs the increase in lanthanum concentration appears slightly before the increase in calcium (white arrows).
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carbonate–treated animals, even in the presence of a se-
vere mineralization defect [2]. This again is in line with
an indirect effect of lanthanum on bone mineralization
that occurs secondary to the element’s high phosphate
binding capacity.
CONCLUSION
We have shown lanthanum to be present mainly at
the outer edge of the mineralized bone in chronic re-
nal failure rats receiving 2000 mg/kg/day for 12 weeks.
There was no obvious relationship with the amount of
osteoid, and no relationship with the type of renal os-
teodystrophy. Lanthanum was found mostly at bone sur-
faces (both active mineralizing and quiescent surfaces),
with lower concentrations in deeper bone, although the
contrast is less under conditions of high bone turnover.
After a washout period of 2 to 4 weeks, lanthanum local-
ization remained similar, while the mineralization defect
disappeared. Possible mechanisms for deposition at bone
surfaces include binding of lanthanum to the organic ma-
trix, heteroionic exchange with calcium, and precipitation
of insoluble amorphous lanthanum phosphate.
ACKNOWLEDGMENTS
X-ray microfluorescence analysis could be performed thanks to a
successful application for beam time at the European Synchrotron Ra-
diation Facility in Grenoble, France. Lanthanum carbonate used in this
study was kindly provided by Shire Pharmaceutical Development Ltd.
(Basingstoke, UK). The authors also wish to thank D. De Weerdt for
his help with figures.
Reprint requests to Patrick C. D’Haese, Department of Nephrology,
University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium.
E-mail: Patrick.DHaese@ua.ac.be
REFERENCES
1. MALLUCHE HH, MONIER-FAUGERE MC: Hyperphosphatemia: Phar-
macologic intervention yesterday, today and tomorrow. Clin
Nephrol 54:309–317, 2000
2. BEHETS GJ, DAMS G, VERCAUTEREN SR, et al: Does the phosphate
binder lanthanum carbonate affect bone in chronic renal failure
rats? J Am Soc Nephrol 15:2219–2228, 2004
3. RODRIGUEZ M, FELSENFELD AJ, LLACH F: Aluminum administration
in the rat separately affects the osteoblast and bone mineralization.
J Bone Miner Res 5:59–67, 1990
4. SEDMAN AB, ALFREY AC, MILLER NL, GOODMAN WG: Tissue and
cellular basis for impaired bone formation in aluminum-related os-
teomalacia in the pig. J Clin Invest 79:86–92, 1987
5. D’HAESE PC, SPASOVSKI GB, SIKOLE A, et al: A multicenter study
on the effects of lanthanum carbonate (FosrenolTM) and calcium
carbonate on renal bone disease in dialysis patients. Kidney Int 63
(Suppl 85):S73–S78, 2003
6. PRIEST ND: The distribution and behaviour of heavy metals in the
skeleton and body: Studies with bone-seeking radio-nuclides, chap.
5, in Trace Metals and Fluoride in Bones and Teeth, edited by Priest
ND, Van de Vyver FL, Boca Raton, CRC Press, 1990, pp 83–
139
7. D’HAESE PC, COUTTENYE MM, GOODMAN WG, et al: Use of the low-
dose desferrioxamine test to diagnose and differentiate between pa-
tients with aluminium-related bone disease, increased risk for alu-
minium toxicity, or aluminium overload. Nephrol Dial Transplant
10:1874–1884, 1995
8. VAN LANDEGHEM GF, DE BROE ME, D’HAESE PC: Al and Si: Their
speciation, distribution, and toxicity. Clin Biochem 31:385–397,
1998
9. VERBUEKEN AH, VAN DE VYVER FL, VAN GRIEKEN RE, et al: Ul-
trastructural localization of aluminum in patients with dialysis-
associated osteomalacia. Clin Chem 30:763–768, 1984
10. FIEJKA M, FIEJKA E, DOUGASZEK M: Effect of aluminum hydroxide
administration on normal mice: tissue distribution and ultrastruc-
tural localization of aluminium in liver. Pharmacol Toxicol 78:123–
128, 1996
11. VAN LANDEGHEM GF, D’HAESE PC, LAMBERTS LV, et al: Aluminum
speciation in cerebrospinal fluid of acutely aluminum-intoxicated
dialysis patients before and after desferrioxamine treatment; a step
in the understanding of the element’s neurotoxicity. Nephrol Dial
Transplant 12:1692–1698, 1997
12. GOODMAN WG, DUARTE ME: Aluminum: Effects on bone and
role in the pathogenesis of renal osteodystrophy. Miner Electrolyte
Metab 17:221–232, 1991
13. SUSINI J, SALOME´ M, FAYARD B, et al: The scanning x-ray microprobe
at the ESRF “X-Ray Microscopy” beamline. Surf Rev Lett 9:203–
211, 2002
14. SUN J, XUE M, KIKUCHI M, et al: Effects of Sr-hydroxyapatite micro-
crystal on cultured cell. Biomed Mater Eng 4:503–512, 1994
15. PRIEST ND: The biological behaviour and bioavailability of alu-
minum in man, with special reference to studies employing
aluminum-26 as a tracer: Review and study update. J Environ Monit
6:375–403, 2004
16. MAYER I, LAYANI JD, GIVAN A, et al: La ions in precipitated hydrox-
yapatites. J Inorg Biochem 73:221–226, 1999
17. D’HAESE PC, COUTTENYE MM, LAMBERTS LV, et al: Aluminum, iron,
lead, cadmium, copper, zinc, chromium, magnesium, strontium, and
calcium content in bone of end-stage renal failure patients. Clin
Chem 45:1548–1556, 1999
